Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure

Advanced Epithelial Ovarian Cancer (EOC) patients frequently relapse by 24 months and develop resistant disease. Research on EOC therapies relies on cancer cell lines established decades ago making Patient Derived Xenografts (PDX) attractive models, because they are faithful representations of the o...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Colombo, Pierre-Emmanuel, du Manoir, Stanislas, Orsetti, Béatrice, Bras-Gonçalves, Rui, Lambros, Mario B., MacKay, Alan, Nguyen, Tien-Tuan, Boissiére, Florence, Pourquier, Didier, Bibeau, Frédéric, Reis-Filho, Jorge S., Theillet, Charles
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2015
Sujets:
Research Paper
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4695063/
https://ncbi.nlm.nih.gov/pubmed/26334103
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires